To facilitate scientific collaboration on polygenic risk scores (PRS) research, we created an extensive PRS online repository for 49 common cancer traits integrating freely available genome-wide association studies (GWAS) summary statistics from three sources: published GWAS, the NHGRI-EBI GWAS Catalog, and UK Biobank-based GWAS. Our framework condenses these summary statistics into PRS using various approaches such as linkage disequilibrium pruning / p-value thresholding (fixed or dataadaptively optimized thresholds) and penalized, genome-wide effect size weighting. We evaluated the PRS in two biobanks: the Michigan Genomics Initiative (MGI), a longitudinal biorepository effort at Michigan Medicine, and the population-based UK Biobank (UKB). For each PRS construct, we provide measures on predictive performance, calibration, and discrimination. Besides PRS evaluation, the Cancer-PRSweb platform features construct downloads and phenome-wide PRS association study results (PRS-PheWAS) for predictive PRS. We expect this integrated platform to accelerate PRS-related cancer research.
Introduction
Since 2005, genome-wide association studies (GWAS) have successfully uncovered many common genetic variants associated with a plethora of complex traits and disorders [1-3]. Translation of these findings into clinical practice to improve presymptomatic screening and patient care is a major aspiration in the research community. However, genetic risk factors for complex diseases like cancer usually have relatively small risk effects and/or low frequencies and thus only have limited ability as individual predictors of risk in the overall population. Alternatively, the integration of all common risk variants into a single biomarker, called a polygenic risk score (PRS), represents a widely used approach for potentially identifying high-risk individuals at the highest levels of PRS [4] [5] [6] . For example, it was shown that PRS for five common complex diseases (coronary artery disease, atrial fibrillation, type 2 diabetes, inflammatory bowel disease, and breast cancer) have the potential to detect individuals at significantly higher genetic risk [4] that might benefit from intensified screening efforts, prophylactic prevention or earlier treatment. Several challenges have to be overcome for constructing a PRS that incorporates state of the art scientific knowledge: one needs (1) summary statistics from an independent discovery GWAS with phenotype and ancestry matching the target study [7] ; (2) individual-level genetic data of a sufficiently large cohort to correct for linkage disequilibrium (LD) between genetic variants; and (3) a computationally efficient method to calculate each PRS and to find the best PRS construct for the target cohort.
The gold standards for GWAS to define PRS constructs are independent, large GWAS analyses or GWAS meta-analyses. Full summary statistics enable exploration of the complete spectrum of PRS construction methods, e.g., those that determine the optimal inclusion p-value threshold of risk variants for prediction, which often deviates from the standard threshold for genome-wide significance (P-value ≤ 5x10 -8 ). So far, several cancer GWAS research groups and consortia have openly shared their full GWAS summary statistics with the research community: ovarian carcinoma [8, 9] , breast cancer [10, 11], prostate cancer [12] , colorectal cancer [13] , and cervical carcinoma [14] . Other groups have released variants that reached an arbitrarily chosen p-value threshold below genome-wide significance (e.g., P-value < 10 -5 ) [15] . In addition to complete or partial GWAS summary statistics, lists of genome-wide significant hits are available for nearly all published GWAS results. The NHGRI-EBI GWAS Catalog [2] (https://www.ebi.ac.uk/gwas/) curates and stores published risk variants for a plethora of traits in a structured database, offering a convenient and efficient way to extract GWAS hits for automated processing.
Alternative and growing sources for publicly available GWAS summary statistics across a large ensemble of diseases use UK Biobank genotype and phenotype data [16] , adjusting for population stratification and/or relatedness between individuals ( [17] ; http://www.nealelab.is/uk-biobank and https://www.leelabsg.org/resources). These biobank-based approaches accessed thousands of phenotypes and traits that were defined in efficient automated fashion, e.g., by ICD10 diagnosis category, with specific phenotype defining algorithms like PHESANT [18] or PHEWAS CODES [19] , or even with consortium-based curated phenotype constructs using the content of the electronic health records (EHR) (FINNGEN; https://www.finngen.fi/en/researchers/clinicalendpoints).
Another important aspect of finding a suitable set of GWAS summary statistics for a PRS is the mapping of the discovery GWAS trait, here the cancer phenotype, with the trait of interest in the target study. GWAS efforts usually balance specificity and sample size to maximize power for discovery. Consequently, the analyzed phenotype definition might not necessarily represent an ideal match to the phenotype of the target study. Also, differences in diagnosis coding practices in EHR systems, e.g., the preference for certain diagnoses due to billing purposes, might limit the transferability of phenotype definitions across cohorts, even if the same coding systems were used [20] .
The simplest form of PRS construction requires two things: a selected set of independent risk variants with estimated or weighted risk effect sizes (say PRS construction methods and their underlying variant selection procedures can roughly be categorized into four groups: (i) fixed P-value thresholds of independent risk variants, e.g., "GWAS hits," variants that reached genome-wide significance (with ܲ ൏ 5 ൈ 1 0 ି ଼ ; (ii) LD pruning (actually clumping) / P-value thresholding ("P&T") of summary statistics that increases power by determining the most predictive P-value cutoff that can be above or below genome-significance [6]; (iii) genome-wide PRS that consider the full GWAS summary statistics after modeling LD, applying shrinkage or Bayesian approaches, e.g., LDpred and lassosum, [21] [22] [23] [24] and (iv) methods that use individual-level data from a GWAS to determine an optimal set of independent predictors through Bayesian spike and slab or mixture priors [25] . The first two approaches typically use the originally reported effect sizes for weighting, while the latter two approaches model LD and/or shrink effect sizes. All methods require a reference panel for LD estimation that ideally resembles or matches the genotype data underlying the discovery GWAS source. Since most only have summary statistics and not individual-level data of the discovery study, we will use only the first three approaches for PRS construction, i.e., fixed P-value thresholds, LD pruning / P-value thresholding, and Lassosum. https://www.cancer.gov/types/common-cancers; estimated incidence of 40,000 or more in the United States in 2019). As of November 9, 173 PubMed articles on PRS and cancer have been published in 2019, more than double the previous high of 86 set in 2018, indicating the rapid growth in collection, curation, and generation of genetic data.
These studies typically employ construction methods (i) and (ii) as described above, although joint variant models are becoming more common because they generally outperform methods (i) and (ii) and advanced software has made joint modeling more computationally efficient for large sample sizes [26, 27] . Several publications constructed PRS for cancer traits using different methods [28] [29] [30] (Table 1) .
We also make the summary statistics for the phenome-wide association study (PheWAS) available. Thus, this centralized and unified platform is a timely attempt to accelerate cancer research related to PRS.
Our repository contributes to the new and necessary work of democratizing PRS constructions and applications for several cancers under a uniform analytic framework to eventually develop transferable risk scores with clinical utility. We also offer phenome-wide exploration of PRS association through PRS-PheWAS, a tool previously introduced by this group [31, 32] .
Results

PRS Construction
We screened the GWAS Catalog, PubMed, and UK Biobank GWAS efforts for any cancer GWAS summary statistics that were reported for European ancestry, to match the predominantly European cohorts of MGI and UKB, and that were openly available, i.e., did not require contacting the main authors or any form of written approval process.
We identified 232 source sets that reported complete information for each tested single nucleotide polymorphisms (SNP) (position [and/or dbSNP ID], effect allele, effect estimate, p-value, and, ideally, effect allele frequency). We obtained 188 SNP sets based on UKB GWAS, 29 based on excerpts from the GWAS Catalog, and 20 from large GWAS or GWAS meta-analyses (Table S1 & 
S2).
We manually matched the traits of the identified cancer GWAS to cancer traits of MGI and UKB PheWAS-codes and analyzed each GWAS source separately, generating PRS for each. The discovery GWAS traits of the 232 source sets approximated 68
cancer PheWAS-codes of the MGI phenome and 21 PheWAS-codes in the UKB phenome (Table S1 & S2). Following the scheme in Figure 1 and Table 2 , we generated PRS using the "P & T" and/or "lassosum" approach and also generated PRS using fixed P-value thresholds after LD clumping (P-value ≤ 5x10 -5 , 5x10 -6 , 5x10 -7 , 5x10 -8 ["GWAS Hits"], or 5x10 -9 ). Using these methods and the available GWAS sources, we generated a total of 1,292 PRS (1,080 PRS for the MGI cohort and 212 PRS for the UKB cohort) ( Table S3 ).
PRS Evaluation
We tested the association between each PRS and its corresponding cancer trait and evaluated each PRS in terms of performance (pseudo-R 2 ), accuracy (Brier score), discrimination (area under the receiver operating characteristic curve [AUC]), and calibration (Hosmer-Lemeshow test) . Finally, we tested their utility for risk stratification, i.e., their ability to enrich cases in five selected top percentiles (1, 2, 5, 10, and 25%) versus the rest of the PRS distribution (Figure 1) .
As an initial filtering step, we removed 625 PRS (48% of total PRS considered) that
were not significantly (603 PRS with P > 0.05) or negatively (241 PRS) associated with their corresponding cancer trait in MGI and/or UKB. The majority of these filtered PRS were either based on discovery GWAS with small sample sizes that often did not identify any genome-wide significant hits or were evaluated for diseases with few cases or both, indicating a potential lack of power in our analysis. A total of 667 PRS for 49 different cancer traits were positively and significantly associated with their corresponding cancers in MGI (478 PRS; 49 cancer traits) and UKB (189 PRS; 19 cancer traits) ( Table S3 ).
Comparison of Performance Metrics:
In general, we found that the ranking by pseudo-R 2 ensured strong performance across other metrics related to discrimination, accuracy, and overall association of PRS constructs for their specific cancers. Conversely, the enrichment analyses in the extreme PRS percentiles (e.g., top 5% versus rest) was not always concordant with the selection of optimal PRS based on pseudo-R 2 , showing that performance in the extreme tails could be optimized by a modified criterion that focuses on extremes of the risk distribution [33] .
An example evaluation is shown in Figure S1 ).
Comparison across GWAS Sources:
We also explored the influence of various GWAS sources on the predictive performance of PRS. As an illustrative example, we again focus on breast cancer PRS, but now consider PRS constructed from different breast cancer GWAS sources, using for each source the method that yielded the highest pseudo-R 2 ( Table S3 .
Comparison of Performance Across Methods: First, we explored the benefit of p-value thresholding for the pre-filtered risk variants of the GWAS Catalog. Compared to the GWAS hits only approach, i.e., only perform LD-clumping of risk variants with P <= 5x10 -8 , the P-value thresholding step of the P&T PRS construction improved PRS performance, as previously reported [52] . This implied that P-value thresholding might to be beneficial even for the relatively sparse sets of GWAS hits reported in the GWAS Catalog ( Figure S2 ).
The P&T approach will, by definition, also cover fixed p-value thresholds in its tuning parameter optimization, i.e., the final P&T PRS will be based on the p-value threshold with the highest pseudo-R 2 and thus perform at least as well as any tested fixed p-value thresholds. Therefore, we limited our next comparison of PRS methods for full summary statistics to P&T and lassosum PRS. We assessed both methods for different GWAS sources in MGI (58 PRS) and UKB (12 PRS). We found that both methods ranked comparably, i.e., a GWAS source that produced a lassosum PRS with high pseudo-R 2 also produced a P&T PRS with high pseudo-R 2 and vice versa (Spearman's rank correlation: rho > 0.937; (Figure S3 ).
Comparison of Performance across Cancers: Next, we were interested in comparisons between PRS across traits to assess overall performance and general differences between cancer traits. Our observed variations between these cancer PRS likely recapitulates the different genetic architectures of cancers in combination with their prevalences in the discovery and evaluation cohorts. First, the prevalence impacted the ability to identify true associations in the discovery GWAS and also affected our capacity to observe significant effects in the PRS performance evaluation.
Comparison of Performance across Cohorts:
The two evaluation cohorts, MGI and UKB, varied in, among other things, their sample sizes, their use of diagnosis code systems, and their recruitment mechanisms, with UKB representing a population-based cohort and MGI an EHR-based, cancer-enriched cohort. We limited a comparison of the cancer PRS to the top-ranked PRS for 19 cancers that were present for both cohorts. We selected the top PRS for each cancer within each cohort, i.e., their GWAS source and method might be different between MGI and UKB.
We noticed the same ranking of AUC values for most cancer PRS but found significantly higher estimates for cancer of brain, cancer of brain / nervous system, colorectal cancer, and prostate cancer in UKB than in MGI ( Figure S4) . The former two estimates might reflect the different underlying GWAS sources, while the latter two might be inflated in UKB due to overlapping samples between their discovery GWAS meta-analyses and the UKB cohort [12, 15] . The other 15 cancers showed a similar ranking of AUC estimates in both cohorts that ranged between "Cancer of other lymphoid, histiocytic tissue" (AUC MGI : 0.527, AUC UKB : 0.532) and highest for "chronic lymphoid leukemia" (AUC MGI : 0.682, AUC UKB : 0.690). AUC values tended to be slightly higher for UKB than for MGI, while confidence intervals were mostly smaller in UKB corresponding to their (often) larger observed effective sample sizes.
A similar comparison of the enrichment of cases in the top 10% versus bottom 90% revealed a lack of power for many cancer PRS in MGI with OR <= 1.3, but a relatively consistent ranking from PRS for pancreatic cancer (MGI OR Top10% : 1.37 and UKB OR Top10% : 1.64) to prostate cancer (MGI OR Top10% : 3.65 and UKB OR Top10% : 3.97).
Overall enrichment effects were often stronger in UKB compared to MGI, reflecting the larger sample sizes of these cancers but also indicated a disparity between populationand hospital-based controls ( Table 1 & Table S6 ; Figure S5 ). However, when comparing the enrichment of cases for two PRS that were well-powered in both cohorts (PRS for breast cancer and chronic lymphoid leukemia), we found it to be strikingly comparable across all tested percentiles (1, 2, 5, 10, and 25% versus rest; Figure 2 ).
Phenome-wide Association Analyses
Beyond case enrichment and risk stratification, PRS can also be used in phenome-wide screenings to uncover secondary trait associations through shared genetic risk factors [31, 32] . These secondary traits might uncover features in the EHR that occur before cancer diagnosis and thus could represent important predictors for cancer outcomes.
From the generated PRS for 49 cancer traits, we selected 13 PRS in MGI and 18 PRS in UKB (whose association with their corresponding cancer traits reached phenomewide significance) for phenome-wide screens of PRS associations. In total, we observed phenome-wide significant associations between 21 cancer PRS and 150 different secondary traits (Table S5 ). We performed "Exclusion-PRS-PheWAS" (i.e., removed primary cancer cases and repeated the phenome-wide analysis) to assess if the identified secondary associations were mainly driven by the primary cancer trait, e.g., through intensified screening or represent post-treatment effects [31] . While the exclusion of cases markedly decreased case counts of secondary traits, we still identified secondary traits that remained significantly associated with the corresponding cancer PRS (Table 7&8 , Table S5 ). Most of the secondary traits in MGI that remained phenome-wide significant in the Exclusion-PRS-PheWAS, e.g., skin cancer PRS associated with actinic keratosis or thyroid cancer PRS associated with hypothyroidism, were reported in our previous studies [32, 53] . Due to the larger sample sizes for most traits in UKB compared to MGI (Table S6) Table   S5 ). Deeper explorations and replications are needed to understand these observed associations and to distinguish between spurious and genuine associations.
Online Visual Catalog: Cancer PRSweb and R package Rprs
In our current study, we compared three PRS construction methods for 68 cancer traits using over 232 sets of GWAS summary statistics. By doing so, we created a large number of PRS in which predictive or enrichment properties differed between GWAS source, PRS method, and/or evaluation cohort. After assessing 1,292 constructed PRS, we found PRS for 49 different cancer traits that we deemed to have predictive value. In our explorations, we established that it could be beneficial to select PRS with certain predictive properties for a specific application instead of using one PRS for all applications. Also, it could be computationally more convenient to use a slightly less powerful PRS based on a fewer number of SNPs than to use a PRS that is based on a few hundred thousand variants. To allow the user the option to explore various PRS constructs, we created PRSweb (http://prsweb.sph.umich.edu), an interactive and intuitive web interface, to explore the available PRS constructs for 49 different cancer traits as well as their performance metrics and suitability for risk stratification, association studies, or other PRS applications.
After an initial selection menu for cancer trait and evaluation cohort (MGI or UKB) We also implemented a search interface for each phenotype/PheCode to provide insights into the ICD-codes underlying the primary cancers as well as the traits of our EHR-derived MGI and UKB phenomes. A methods section describes the applied approaches.
Discussion
In our study, we constructed and evaluated a large set of cancer PRS using more than 200 different sources of GWAS summary statistics. We applied three common PRS construction methods: GWAS hits, LD pruning/P-value thresholding, and lassosum.
While doing so, we created an online repository called "PRSweb"
(http://prsweb.sph.umich.edu/) with over 600 PRS for 49 cancer traits.
We observed that construction and resulting performance of PRS depend on multiple factors, including GWAS source, PRS method, and evaluation cohort.
Researchers who plan to apply PRS in their projects are often faced with an agony of choice from a set of PRS in the current literature or might not find predictive PRS at all.
Furthermore, if PRS are available, a direct comparison of multiple constructs is often not feasible, as their performance can be cohort-specific and limited by available sample size.
To alleviate this situation, we generated "PRSweb" that could serve as a central hub for standardized PRS. PRSweb so far offered a selection and exploration of PRS based on publicly available cancer GWAS data. The platform integrated the evaluation of the rich EHR data of two independent biobanks, MGI and UKB. In our initial version of PRSweb, we focused on cancer traits because MGI is enriched for cancer.
There are several remaining challenges in developing PRS, and we will discuss the following four: access to independent GWAS summary statistics, mapping of trait definitions between discovery and evaluation cohorts, power limitations, and finally, transferability of PRS across cohorts and ancestries.
Access to independent GWAS summary statistics
Limited accessibility to full summary statistics for cancer GWAS in the published literature resulted in a lack of PRS constructs for many cancers. With the tendency to form large consortia and to integrate available biobank data comes another challenge, namely the potential overlap between the discovery and evaluation cohorts and, thus, potential overfitting. For our current study, we used GWAS that are to the best of our knowledge, independent from MGI. Since UKB is a popular and widely used resource, the assumption of independence of large GWAS efforts from UKB, does not always hold true as we have seen for the large colorectal cancer GWAS [15] . In the future, the assessment of independence of GWAS from PRS construction will become more challenging, especially when relying on GWAS databases (e.g., the GWAS Catalog), where the distinction of contributing cohorts might not be obvious from a database entry alone. An alternative solution, especially for consortia joining large GWAS, is leave-one-out meta-analysis where in addition to the full meta-analysis results, a separate set of meta-analysis results will be provided for each contributing cohort so that each resulting leave-one-out meta-analysis can be shared and used for PRS generation in that cohort to avoid overfitting.
We anticipate a more accessible landscape of high-quality full GWAS results in the near future, not only for cancer. First, funding agencies are updating their policy regarding access to GWAS summary statistics of funded projects , e.g., the US National Institutes of Health (NIH), (https://grants.nih.gov/grants/guide/notice-files/NOT-OD-19-023.html). Secondly, biobank studies are growing in numbers and size and, when connected to EHR data, enable GWAS for thousands of traits each [53] . In addition, global efforts are forming that will enable even more powerful phenome x GWAS metaanalyses through collaboration, likely reaching sample sizes that can compete with classical disease-specific consortia [57] .
Mapping of Trait Definitions
One of the premises for PRS utility is the resemblance of the original trait in the discovery GWAS with the trait of the evaluation cohort.
For our current study, we relied on EHR-based cohorts and defined cancer via PheWAS codes that are adopted from ICD codes. It is important to bear in mind that we used EHR-based diagnosis data that per se were not collected for research. Besides misclassification, EHR-derived phenomes might be prone to selection and recruitment biases that can negatively impact power or result in false-positive associations [53] . ICD codes usually serve administrative and billing purposes and often lack the specificity found in the discovery GWAS. Due to the difference in trait definitions, we often had to fall back to the broad phenotype definition in the EHR cohorts and, by doing so, might have negatively influenced the predictive power for PRS [58] . Still, the chosen phenotype definitions represent valid and common cancer groupings that are frequently used in clinical and research applications [59] .
Power Limitations
For our project, we used data from MGI, a medical center-based cohort, and UKB, a population-based cohort. Due to MGI's recruitment mechanism through surgery, the observed case counts in MGI reflected the numbers of adult (18+) patients that underwent a surgical procedure and had at least one corresponding cancer diagnosis in their medical records. The case counts in UKB, a rather healthy subset of the older (40-69) British population [60] , might be even lower than the population's cancer prevalence. We observed an enrichment of many cancers in MGI compared to UKB, especially for rarer cancers like thyroid cancer, but generally registered more cases in the UKB because its cohort is ten times larger (Table S6 ). In addition, MGI's recruitment through surgical procedures likely resulted in a relative depletion of blood cancers (e.g., leukemia, lymphoma, and myeloma), since affected patients undergo surgery less frequently than somatic cancer patients. As a consequence, we often had sufficient power to evaluate and analyze PRS for these diseases in UKB but not MGI.
One may be interested in defining a combined phenotype of "any cancer" for a composite cancer PRS with a maximal sample size. We defined this phenotype in UKB (with 69,190 cases of any cancer; Tables S6 & S7 , Figures S7 & S8) , performed a GWAS that revealed known risk variants for numerous cancers, and created an "any cancer" PRS using our established methods. The lassosum PRS with a choice for 179 variants performed best amongst the constructs (Table S8 ). However, while defining such a composite phenotype, we have to remember that the endpoint is a heterogeneous mix of various cancers, and the discovery will be driven by the cancers with larger numbers of cases or strong risk effects in the discovery (UKB) and evaluation (MGI) cohort. In the PRS PheWAS in MGI, we saw many related traits associated with the overall PRS. No secondary trait reached phenome-wide significance in the exclusion PRS-PheWAS (Table S9; Figure S9 ). We incorporated this overall PRS constructs in Cancer-PRSweb.
Besides accessible sample sizes, the ability to create predictive PRS depends on the cancers' "chip heritability," i.e., the variance explained through polygenic variants of genotyped and imputed datasets. A previous study on six common cancers found that chip heritability estimates can vary substantially for cancers (e.g., estimated heritability for prostate cancer: 27%, breast cancer 12%, and pancreatic cancer 7%) [ [56] . Consequently, approaches that only consider GWAS hits might work better for the former, while less conservative p-value thresholds or genome-wide PRS methods might work better for the latter cancer traits.
Transferability of PRS across cohorts
In our current study, we constructed and evaluated PRS in individuals of broadly European ancestry. However, we recognize the need to also construct and share PRS for non-European ancestry groups, especially because of the limited transferability of PRS across ancestries and ethnicities [7] . The integration of PRS for non-European individuals into our platform PRSweb so far is hampered by the scarcity of GWAS data for diverse ancestry groups [63] , and by the limited diversity in MGI and UKB, both encompassing predominantly European ancestry individuals.
Differences in genotyping and sequencing strategies can also negatively impact comparability between studies. Ideally, genotype data in the discovery GWAS, the LD reference panel, and the evaluation cohort should be comparable in quality, density and LD structure for ultimate compatibility. GWAS usually rely on genotyping arrays that can differ in composition and density of variants. Phasing and imputation methods are constantly improving thanks to growing reference panels and refined methods [64] and are essential in harmonizing genotype data across cohorts. However, the achievable accuracy is dependent on the study's sample size and variant density. Consequently, a PRS that was constructed from a large and marker-dense GWAS might not be directly transferable to smaller, sparser genotype data.
In our current analysis of two genotype datasets that differed in genotype density and sample size, we found that the tuning parameters of PRS established separately for MGI and UKB were ranked similarly in terms of their resulting predictive performance.
This indicated that sharing of PRS constructs might represent a feasible and convenient alternative to computationally expensive PRS methods and evaluations.
Conclusions
By generating PRS from a large collection of freely available cancer GWAS summary statistics and by evaluating them in two independent biobanks, we created the analytical backbone of PRSweb, an online repository for cancer PRS offering detailed constructs and comparisons. We designed PRSweb for transparency and convenience to democratize PRS research. So far, we included PRS constructs and analyses for 49 different cancer traits that showed promising performance in MGI and/or UKB. We anticipate the inclusion of additional PRS constructs and methods in an upcoming version of PRSweb that also will expand our focus beyond cancers. overlapped with the imputed MGI data (see above). Two random subsets of 5,000 and 10,000 unrelated, White British individuals were used for LD analyses of UKB-based summary statistics.
Phenome generation
MGI
The MGI phenome was used as the discovery dataset and was based on ICD9-CM and ICD10-CM code data for 38,360 unrelated, genotyped individuals of recent European ancestry. Longitudinal time-stamped diagnoses were recoded to indicators for whether a patient ever had given a diagnosis code recorded by Michigan Medicine. These ICD9-CM and ICD10-CM codes were aggregated to form up to 1,857 PheWAS traits using the PheWAS R package (as described in detail elsewhere [68, 75] ). For each trait, we identified case and control samples. To minimize differences in age and sex distributions, avoid extreme case-control ratios, and reduce the computational burden, we matched up to 10 controls to each case using the R package "MatchIt" [76] . Nearest neighbor matching was applied for age and the first four principal components of the genotype data (PC1-4) using Mahalanobis distance with a caliper/width of 0.25 standard deviations. Exact matching was applied for sex and genotyping array. A total of 1,689
case-control studies with >50 cases were used for our analyses of the MGI phenome.
UK Biobank
The UK Biobank phenome was used as a replication dataset and was based on ICD9
and ICD10 code data of 408,961 White British [74] , genotyped individuals that were similarly aggregated to PheWAS traits as MGI (as described elsewhere [77] ). In contrast to MGI, there were many pairwise relationships reported for UKB participants.
To retain a larger effective sample size for each phenotype, we first selected a maximal set of unrelated cases for each phenotype (defined as no pairwise relationship of 3 rd degree or closer [11, 73]) before selecting a maximal set of unrelated controls unrelated to these cases. Similar to MGI, we matched up to 10 controls to each case using the R package "MatchIt" [76] . Nearest neighbor matching was applied for birthyear and PC1-4 (Mahalanobis-metric matching; matching window caliper/width of 0.25 standard deviations), and exact matching was applied for sex and genotyping array. A total of 1,419 case-control studies with >50 cases each were used for our analyses of the UK Biobank phenome.
On average, we were able to match 9 controls per case in the MGI phenome and 9.9 controls per case in the UKB phenome. Additional phenotype information for MGI and UK Biobank is included in (Table S6) .
PRS Structure
PRS combine information across a defined set of genetic loci, incorporating each
locus's association with the target trait. The PRS for patient j takes the form
where i indexes the included loci for that trait, weight ߚ is the log odds ratios retrieved from the external GWAS summary statistics for locus i, and ‫ܩ‬ is a continuous version of the measured dosage data for the risk allele on locus i in subject j.
In order to construct a PRS, one must determine which genetic loci to include in the PRS and their relative weights. Below, we obtain GWAS summary statistics from several different sources, resulting in several sets of weights for each trait of interest.
For each set of weights, we consider several strategies for determining which genetic loci to include in the PRS construction. 
Sources of GWAS summary statistics
GWAS Catalog
We downloaded previously reported GWAS variants from the NHGRI-EBI GWAS Catalog (file version: r2019-05-03, https://www.ebi.ac.uk/gwas/) [78, 79] . Single nucleotide polymorphism (SNP) positions were converted to GRCh37 using variant IDs from dbSNP (build 151; UCSC Genome Browser, http://genome.ucsc.edu/) after updating outdated dbSNP IDs to their merged dbSNP IDs.
Entries with missing risk alleles, risk allele frequencies, or SNP-disease odds ratios were excluded. If a reported risk allele did not match any of the reported forward strand alleles of a non-ambiguous SNP (not A/T or C/G) in the imputed MGI genotype data (which correspond to the alleles of the imputation reference panel), we assumed minus-strand designation and corrected the effect allele to its complementary base of the forward strand. Entries with a reported risk allele that did not match any of the alleles of an ambiguous SNP (A/T and C/G) in our data were excluded at this step. We only included entries with broad European ancestry (as reported by the NHGRI-EBI GWAS Catalog) to match ancestries of discovery GWAS and target cohorts (MGI and UKB). As a quality control check, we compared the GWAS Catalog reported risk allele frequencies (RAF) with the RAF in MGI individuals. We then excluded entries whose RAF deviated more than 15%. This chosen threshold is subjective and was based on clear differentiation between correct and likely flipped alleles on the two diagonals ( Figure S6) , as noted frequently in GWAS meta-analyses quality control procedures [80] . For SNPs with multiple entries, we kept the SNP with the most recent publication date (and smaller p-value, if necessary) and excluded the others.
Large GWAS meta-analyses
We downloaded full GWAS summary statistics made available by the "Breast Cancer . In addition, we extracted partial GWAS summary statistics that accompanied recent publications but were incomplete, i.e. reporting only SNPs below a certain p-value threshold [15, [81] [82] [83] . GWAS summary statistics were harmonized and, if needed, lifted over to human genome assembly GRCh37. In this paper, this source is referred to as "Large GWAS".
UK-Biobank-based GWAS
We downloaded UK Biobank based GWAS summary statistics from two public repositories.
The first set of UK Biobank GWAS summary statistics were based on the analysis of up to 408,961 White British European-ancestry samples (https://www.leelabsg.org/resources). SNP-disease odds ratios were estimated using logistic mixed modeling adjusting for sample relatedness, and p-values were estimated using saddlepoint approximations (SAIGE method [17] ) to calibrate the distribution of score test statistics and, thus, control for unbalanced case-control ratios. The underlying phenotypes were auto-curated phenotypes based on the PheCodes of the PheWAS R package [68, 75, 77] similar to the phenomes used in our study and in the following are referred to as "UKB PHECODE" ( Table S1 ).
The (https://www.finngen.fi/en/researchers/clinical-endpoints). In addition to the "UKB PHECODE" (described above), these three latter sources are referred to as "UKB PHESANT", "UKB ICD10" and "UKB FINNGEN", respectively (Table S1 ).
PRS Construction
For each set of GWAS summary statistics from the above-mentioned sources and each cancer, we develop up to seven different PRS using three different construction methods (Figure 1) . Our goal of this approach was to compare multiple PRS methods and find the method that works best for the various types of GWAS summary statistics.
For the first two construction strategies, we performed LD clumping/pruning of variants with p-values below 10 -4 by using the imputed allele dosages of 10,000 randomly selected samples and a pairwise correlation cut-off at r 2 < 0.1 within 1Mb window. Using the resulting loci, we defined up to five sub-sets of variants with p-values below different thresholds (<5x10 -9 to <5x10 -5 ). These were used to construct a PRS tied to each threshold, where the PRS associated with p-values less than 5x10 -8 is sometimes denoted as "GWAS hits." For the second PRS construction method, we construct many different PRS across a fine grid of p-value thresholds. The p-value threshold with the highest cross-validated pseudo-R2 (see PRS Evaluation below) was used to define the more optimized "Pruning and Thresholding (P & T)" PRS.
As an alternative to the p-value thresholding and "P&T" PRS construction strategies, we also used the software package "lassosum" [22] to define a third type of PRS for GWAS sources with full summary statistics. Lassosum obtains PRS weights by applying elastic net penalization to GWAS summary statistics and incorporating LD information from a reference panel. Here, we used 5,000 randomly selected, unrelated 
PRS Evaluation
For the PRS evaluations, we fit the following model for each PRS and cancer phenotype without adjusting for covariates:
We performed a 5-fold cross validation with the R package "caret" [84] to obtain fitted predictors for the actual PRS evaluations. We used Nagelkerke's pseudo-R 2 [85] to select the tuning parameters within the "P&T" and lassosum construction methods (Pvalue for "P&T" SNP sets; s and λ for lassosum) and kept the PRS with the highest pseudo-R 2 for further analyses. For each PRS derived for each GWAS source/method combination, we assessed the following performance measures relative to observed disease status in MGI and UKB:
(1) overall performance with Nagelkerke's pseudo-R 2 using R packages "rcompanion" [85] , (2) accuracy with Brier score using R package "DescTools" [86] ; (3) ability to discriminate between cases and controls as measured by the area under the receiver operating characteristic (ROC) curve (denoted AUC) using R package "pROC" [87] and (4) calibration using Hosmer-Lemeshow Goodness of Fit test in the R package "ResourceSelection" [88] [89] [90] .
PRS Association Testing
Next, we assessed the strength of the relationship between these PRS and the traits they were designed for. were included to address potential residual confounding and do not provide interpretable estimates due to the preceding application of case-control matching. Firth's bias reduction method was used to resolve the problem of separation in logistic regression (Logistf in R package "EHR") [91] [92] [93] .
To study the ability of the PRS to identify high risk patients, we fit the above model but replacing the PRS with an indicator for whether the PRS value was in the top 1, 2, 5, 10, or 25% among the matched case control cohort.
Phenome-wide Exploration of PRS Associations
We selected PRS that were strongly associated with the cancer trait they were designed for phenome-wide association exploration in the phenomes of MGI and UKB for (pvalue ≤ (0.05 / [#phenotypes in corresponding phenome]); see below).
We conducted PheWAS in MGI and also UKB (if the GWAS source was not based on UKB) to identify additional, secondary phenotypes associated with the PRS [31] . To evaluate PRS-phenotype associations, we conducted Firth bias-corrected logistic regression by fitting model of equation 1 To investigate the possibility of the secondary trait associations with PRS being completely driven by the primary trait association, we performed a second set of PheWAS after excluding individuals affected with the primary or related cancer traits for which the PRS was constructed, referred to as "Exclusion-PRS-PheWAS" as described previously [68] .
Online Visual Catalog: PRSweb
The online open access visual catalog PRSweb was implemented using Grails, a Groovy-and Java-based backend logic, to integrate interactive visualizations and MySQL databases. Interactive PheWAS plots are drawn with the JavaScript library "LocusZoom.js" which is maintained by the UM Center for Statistical Genetics (https://github.com/statgen/locuszoom) and offers dynamic plotting, automatic plot sizing, and label positioning. Additional data-driven visualizations (e.g. temporal relationship plots) were implemented with the JavaScript library "D3.js".
Unless otherwise stated, analyses were performed using R 3.6.1 [94] .
Data availability
Data cannot be shared publicly due to patient confidentiality. Notes: Cancer traits are sorted by observed case counts in MGI. * PRS were scaled to mean = 0 and sd = 1 ** Top 1% versus rest Notes: Cancer traits are sorted by observed case counts in UKB. * PRS were scaled to mean = 0 and sd = 1; ** Top 1% versus rest (153) Neoplasm of unspecified nature of digestive system (158) ; Malignant neoplasm of other and ill-defined sites within the digestive organs and peritoneum (159); Cancer, suspected or other (195); Malignant neoplasm, other (195.1); Benign neoplasm of colon (208); Diverticulosis and diverticulitis (562); Diverticulosis (562.1); Functional digestive disorders (564); Personal history of diseases of digestive system (564.9); Anal and rectal conditions (565); Anal and rectal polyp (565.1) Pancreatic cancer (157) Phlebitis and thrombophlebitis (451) 
